AVI BioPharma Announces $24 Million Direct Equity Placement
AVI BioPharma, Inc. announced that it has entered into definitive agreements with several institutional investors for the purchase of 8 million shares of its common stock at $3.00 per share in a direct equity placement for gross proceeds to the company of $24 million. Investors also will receive four-year warrants to purchase 1.6 million shares of common stock at an exercise price of $5.00 per share.
The securities are being sold pursuant to the company's effective shelf registration statement. Rodman & Renshaw, LLC, acted as the exclusive placement agent on the transaction.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.